US Patent

US11087354 — Combination therapies

Method of Use · Assigned to Genentech Inc · Expires 2034-06-22 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of using cobimetinib fumarate in a combination therapy for treating pathological conditions such as cancer.

USPTO Abstract

The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.

Drugs covered by this patent

cobimetinib-fumarate (COBIMETINIB FUMARATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1776`	—	cobimetinib-fumarate

Patent Metadata

Patent number: US11087354
Jurisdiction: US
Classification: Method of Use
Expires: 2034-06-22
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.